{"title":"2 型糖尿病患者补充鱼油衍生的 Omega-3 脂肪酸后糖脂代谢参数的改善与肠道微生物群和脂代谢物有关。","authors":"Jiayue Xia, Shiyu Yin, Junhui Yu, Jiongnan Wang, Xingyi Jin, Yuanyuan Wang, Hechun Liu, Guiju Sun","doi":"10.3390/nu16213755","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/objectives: </strong>This study aimed to investigate the effects of fish oil-derived omega-3 polyunsaturated fatty acids (omega-3 PUFAs) on gut microbiota and serum lipid metabolites in T2DM.</p><p><strong>Methods: </strong>In a three-month, randomized, double-blind, placebo-controlled study, 110 T2DM patients received either fish oil (<i>n</i> = 55) or corn oil (<i>n</i> = 55) capsules daily. Serum lipids, glycemic parameters, gut microbiota diversity, and lipidomics were assessed.</p><p><strong>Results: </strong>This study found that fish oil-derived omega-3 PUFAs intervention did not significantly lower the fasting plasma glucose levels when compared with the baseline level (<i>p</i> > 0.05). However, serum fasting blood glucose (<i>p</i> = 0.039), glycosylated hemoglobin levels (<i>p</i> = 0.048), HOMA-IR (<i>p</i> = 0.022), total cholesterol (<i>p</i> < 0.001), triglyceride (<i>p</i> = 0.034), LDL cholesterol (<i>p</i> = 0.048), and non-HDL levels (<i>p</i> = 0.046) were significantly lower in the fish oil group compared with the corn oil group after three months of intervention. Also, it altered glycerophospholipid metabolism and gut microbiota. After three months, the fish oil group showed a significantly lower abundance of <i>Desulfobacterota</i> compared with the corn oil control group (<i>p</i> = 0.003), with reduced levels of <i>Colidextribacter</i> (<i>p</i> = 0.002), <i>Ralstonia</i> (<i>p</i> = 0.021), and <i>Klebsiella</i> (<i>p</i> = 0.013). Conversely, the abundance of <i>Limosilactobacillus</i> (<i>p</i> = 0.017), <i>Lactobacillus</i> (<i>p</i> = 0.011), and <i>Haemophilus</i> (<i>p</i> = 0.018) increased significantly. In addition, relevant glycolipid metabolism indicators showed significant correlations with the altered profiles of serum lipid metabolites, intestinal bacteria, and fungi.</p><p><strong>Conclusions: </strong>This study highlights the impact of fish oil-derived omega-3 PUFAs on intestinal microbiota structure and function in patients with type 2 diabetes. The observed decrease in pathogenic bacterial species and the enhancement of beneficial species may have significant implications for gut health and systemic inflammation, both of which are pivotal in managing diabetes. Further research is warranted to comprehensively elucidate the long-term benefits and underlying mechanisms of these microbiota alterations.</p>","PeriodicalId":19486,"journal":{"name":"Nutrients","volume":"16 21","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11547733/pdf/","citationCount":"0","resultStr":"{\"title\":\"Improvement in Glycolipid Metabolism Parameters After Supplementing Fish Oil-Derived Omega-3 Fatty Acids Is Associated with Gut Microbiota and Lipid Metabolites in Type 2 Diabetes Mellitus.\",\"authors\":\"Jiayue Xia, Shiyu Yin, Junhui Yu, Jiongnan Wang, Xingyi Jin, Yuanyuan Wang, Hechun Liu, Guiju Sun\",\"doi\":\"10.3390/nu16213755\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/objectives: </strong>This study aimed to investigate the effects of fish oil-derived omega-3 polyunsaturated fatty acids (omega-3 PUFAs) on gut microbiota and serum lipid metabolites in T2DM.</p><p><strong>Methods: </strong>In a three-month, randomized, double-blind, placebo-controlled study, 110 T2DM patients received either fish oil (<i>n</i> = 55) or corn oil (<i>n</i> = 55) capsules daily. Serum lipids, glycemic parameters, gut microbiota diversity, and lipidomics were assessed.</p><p><strong>Results: </strong>This study found that fish oil-derived omega-3 PUFAs intervention did not significantly lower the fasting plasma glucose levels when compared with the baseline level (<i>p</i> > 0.05). However, serum fasting blood glucose (<i>p</i> = 0.039), glycosylated hemoglobin levels (<i>p</i> = 0.048), HOMA-IR (<i>p</i> = 0.022), total cholesterol (<i>p</i> < 0.001), triglyceride (<i>p</i> = 0.034), LDL cholesterol (<i>p</i> = 0.048), and non-HDL levels (<i>p</i> = 0.046) were significantly lower in the fish oil group compared with the corn oil group after three months of intervention. Also, it altered glycerophospholipid metabolism and gut microbiota. After three months, the fish oil group showed a significantly lower abundance of <i>Desulfobacterota</i> compared with the corn oil control group (<i>p</i> = 0.003), with reduced levels of <i>Colidextribacter</i> (<i>p</i> = 0.002), <i>Ralstonia</i> (<i>p</i> = 0.021), and <i>Klebsiella</i> (<i>p</i> = 0.013). Conversely, the abundance of <i>Limosilactobacillus</i> (<i>p</i> = 0.017), <i>Lactobacillus</i> (<i>p</i> = 0.011), and <i>Haemophilus</i> (<i>p</i> = 0.018) increased significantly. In addition, relevant glycolipid metabolism indicators showed significant correlations with the altered profiles of serum lipid metabolites, intestinal bacteria, and fungi.</p><p><strong>Conclusions: </strong>This study highlights the impact of fish oil-derived omega-3 PUFAs on intestinal microbiota structure and function in patients with type 2 diabetes. The observed decrease in pathogenic bacterial species and the enhancement of beneficial species may have significant implications for gut health and systemic inflammation, both of which are pivotal in managing diabetes. Further research is warranted to comprehensively elucidate the long-term benefits and underlying mechanisms of these microbiota alterations.</p>\",\"PeriodicalId\":19486,\"journal\":{\"name\":\"Nutrients\",\"volume\":\"16 21\",\"pages\":\"\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11547733/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nutrients\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/nu16213755\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrients","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/nu16213755","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
Improvement in Glycolipid Metabolism Parameters After Supplementing Fish Oil-Derived Omega-3 Fatty Acids Is Associated with Gut Microbiota and Lipid Metabolites in Type 2 Diabetes Mellitus.
Background/objectives: This study aimed to investigate the effects of fish oil-derived omega-3 polyunsaturated fatty acids (omega-3 PUFAs) on gut microbiota and serum lipid metabolites in T2DM.
Methods: In a three-month, randomized, double-blind, placebo-controlled study, 110 T2DM patients received either fish oil (n = 55) or corn oil (n = 55) capsules daily. Serum lipids, glycemic parameters, gut microbiota diversity, and lipidomics were assessed.
Results: This study found that fish oil-derived omega-3 PUFAs intervention did not significantly lower the fasting plasma glucose levels when compared with the baseline level (p > 0.05). However, serum fasting blood glucose (p = 0.039), glycosylated hemoglobin levels (p = 0.048), HOMA-IR (p = 0.022), total cholesterol (p < 0.001), triglyceride (p = 0.034), LDL cholesterol (p = 0.048), and non-HDL levels (p = 0.046) were significantly lower in the fish oil group compared with the corn oil group after three months of intervention. Also, it altered glycerophospholipid metabolism and gut microbiota. After three months, the fish oil group showed a significantly lower abundance of Desulfobacterota compared with the corn oil control group (p = 0.003), with reduced levels of Colidextribacter (p = 0.002), Ralstonia (p = 0.021), and Klebsiella (p = 0.013). Conversely, the abundance of Limosilactobacillus (p = 0.017), Lactobacillus (p = 0.011), and Haemophilus (p = 0.018) increased significantly. In addition, relevant glycolipid metabolism indicators showed significant correlations with the altered profiles of serum lipid metabolites, intestinal bacteria, and fungi.
Conclusions: This study highlights the impact of fish oil-derived omega-3 PUFAs on intestinal microbiota structure and function in patients with type 2 diabetes. The observed decrease in pathogenic bacterial species and the enhancement of beneficial species may have significant implications for gut health and systemic inflammation, both of which are pivotal in managing diabetes. Further research is warranted to comprehensively elucidate the long-term benefits and underlying mechanisms of these microbiota alterations.
期刊介绍：
Nutrients (ISSN 2072-6643) is an international, peer-reviewed open access advanced forum for studies related to Human Nutrition. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
